Novel Drug Shows Potential For Treating Leukemia
Date: 23.4.2007
Related articles
Cheap molecule may attack tumors - A cheaply-produced molecule may be the key to treating a variety of cancers, claim Canadian researchers Dicholoroacetate (DCA) has been suggested for years as a possible treatment for certain rare metabolic disorders in children The University of Alberta team, writing in the journal Cancer Cell, now say it could encourage cancer cells to die Experts say much more research will be needed before an effective cancer treatment can emerge Whole article onnews (23.4.2007)
Researchers Develop New Method For Fighting Leukemia - Researchers at Virginia Commonwealth University's Massey Cancer Center have created a new method to improve the antileukemic activity of a novel agent that triggers programmed cell death, a development that could lead to more effective strategies for fighting leukemia and other malignancies The cell death process, or apoptosis, is characteristically impaired in cancer cells One such agent, known as ABT-737, potently blocks the pro-survival effects of two proteins, Bcl-2 and Bcl-xL, according to Steven Grant, M In laboratory experiments, ABT-737 has been shown to be very effective in killing tumor cells Whole article: www (18.1.2007)
Leukemia drug Gleevec may damage heart: study - The study, published Sunday in the online edition of the journal Nature Medicine, followed by reports that 10 patients taking Gleevec for chronic myelogenous leukemia developed severe congestive heart failure "Gleevec is a wonderful drug and patients with these diseases need to be on it "We're trying to call attention to the fact that Gleevec and other similar drugs coming along could have significant side effects on the heart and clinicians need to be aware of this Gleevec, sold under the Glivec in some countries, had worldwide sales of 1 Novartis said the cases of heart failure in Gleevec patients were extremely rare and said those few patients were successfully treated with two drugs that can help heart failure -- ACE inhibitors and carvedilol "Further study is necessary to better understand the relationship between these preclinical studies and their potential impact on the clinical management of patients taking Glivec," the company said in a statement Source (9.8.2006)
The use of quantitative assessment of Wilms tumour gene 1 for monitoring of residual disease in acute myeloid leukemia patients - Polak J, Markova J, Schwarz J, Maaloufova J, Volkova Z, Cermak J, Haskovec C Ustav hematologie a krevni transfuze, Praha BACKGROUND: Despite a considerable effort, the majority of acute myeloid leukaemia (AML) patients do not have a suitable specific molecular marker for monitoring minimal residual disease (MRD) The WT1 expression was significantly elevated (up to 3 orders of magnitude) in peripheral blood samples (PB) of AML patients at diagnosis compared to PB samples of healthy donors (P (2.6.2006)
Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. - Institute of Hematology and Blood Transfusion, Prague, Czech RepublicInstitute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) can relapse even after aggressive therapy and autografts METHODS: As a prerequisite for MRD detection, touch-down reverse transcriptase (RT)-PCR using degenerate primers were used for the diagnostic identification of (H) gene rearrangement(s) We demonstrated MRD in each patient tested, including four of four patients in complete remission following autologous hematopoietic stem cell transplantation (HSCT) and three of three following allogeneic 'mini'-HSCT Source (17.3.2006)
